Myelofibrosis
(MF) is characterized by splenomegaly and fibrotic bone marrow. It is usually the primary form of one of the chronic myeloproliferative disorders. However, sometimes it is secondary to hematological or non-hematological neoplasms, infections, or exposure to drugs or radiation (1). Although marrow fibrosis associated with plasma cell dyscrasia such as multiple myeloma (MM) is reported occasionally, it has not been clearly demonstrated whether coexistent MF in untreated bone marrow is secondary to MM or not (2). In this paper we report a patient in whom MF improved with the recovery from MM after treatment with melphalan and prednisolone (MP).
CASE REPORT
A 67-year-old woman was admitted to our myelofibrosis. At this time measurement of plateletderived growth factor (PDGF) by radioimmunoassay revealed a high value (4,100 pg/ml) in bone marrow supernatant compared with that in peripheral blood in healthy donors (< 800 pg/ml).
DISCUSSION
In recent retrospective studies the incidence of the presenceof idiopathic MF in patients with MMand that of MMin patients with idiopathic MF were estimated to be 8.8% and 4.3%, respectively, in the scattered reports associating MF with MM (3, 4). Vandermolen and colleagues described a classification of MMwith coexistent MF, categorizing them into two groups: plasma cell dyscrasia-marrow fibrosis syndrome and coincident myeloma and myelofibrosis (5). In the present case, except for the absence of tear drop red blood cells, the hematological condition seems to be compatible with coincident myeloma and myelofibrosis, according to Vandermolen et al. Interestingly, it was observed that the MF and MMsimultaneously improved after treatment with alkylating agents. This observation has not been described in previously reports except by Patterson et al, as far as wecan ascertain (6). This finding supports the hypothesis that the development of MFwas secondary to MMin the present patient.
The pathogenesis of bone marrow fibrosis in myeloproliferative disorders and other underlying conditions such as hairy cell leukemia, carcinoma and myeloma is not yet clear. Recently it has been demonstrated that interleukin 6 (IL-6), known as B-cell stimulatory factor 2, is produced by fresh myeloma cell and may play a role in autocrine generation of multiple myelomas (7). IL-6 with IL-3 not only acts synergistically in the proliferation of megakaryocytes in vitro but IL-6 also stimulates platelet production in vivo (8, 9) . In addition, various growth factors known as PDGF, transforming growth factor (TGF)-^, and epidermal growth factor (EGF), which stimulate the proliferation of fibroblasts are contained in platelets (10) (11) (12) .
It has been demonstrated that megakaryocytesstimulate the proliferation of bone marrow fibroblasts by growth-promoting factor similar to PDGF which increases collagen synthesis by target mesenchymal cells (13, 14) . 
